Get all premium features to the best stock analysis tool

Solvonis Therapeutics PLC (LSE:SVNS, OTC:SLVNF), the London-listed biopharmaceutical company, has been granted a Notice of Allowance by the European Patent Office for a composition-of-matter patent covering its lead PTSD treatment. The allowance, which the company described as a "vital milestone", relates to the company's programme developing SVN-114, a drug candidate for post-traumatic stress disorder (PTSD).

Solvonis Therapeutics PLC (LSE:SVNS, OTC:SLVNF), the London-listed biopharmaceutical company developing treatments for addiction and psychiatric disorders, has raised £1.3 million through a share placing. The company is issuing 1.08 billion new shares at 0.12p each.

Solvonis Therapeutics PLC (LSE:SVNS, OTC:SLVNF) has cleared the first hurdle in a US government testing programme for an experimental treatment for cocaine and methamphetamine addiction. The National Institute on Drug Abuse, part of the US government's medical research arm, has agreed to advance the compound, known as SVN-015, into a further round of studies.